Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

AJ Mast | Bloomberg | Getty Images

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Read More: World News | Entertainment News | Celeb News
CNBC

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Markets getting ahead of themselves on rate cuts and risk being ‘self-defeating,’ ECB member says

Markets are “getting ahead of themselves” with rate cut expectations, the president…

Ten years in the creation: secrets of the new King Charles bank notes

The imposing domed halls of the Bank of England are hushed. After…

Trump Media shares fall more than 10%, company says Truth Social to launch TV streaming

Jonathan Raa | Nurphoto | Getty Images Trump Media shares fell by…

Eco-friendly startups are turning to treeless toilet paper

Toilet paper wipes out thousands of acres of Canadian forest each year,…